TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 698154

Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Lippes loop D
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Dalkon shield
Number of subjects: 281

Group type: COMPARATOR
Intervention: All three IUCDs
Number of subjects: 281
Study: 31408088

Group type: EXPERIMENTAL
Intervention: Passive viewing of pictures
Number of subjects: 47

Group type: COMPARATOR
Intervention: Fixation cross
Number of subjects: 47
Study: 31541851

Group type: EXPERIMENTAL
Intervention: Multi-component cognitive behavioral self-help intervention (MCT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Sleep restriction intervention for insomnia (SRT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 104
Study: 28058769

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Exenatide twice daily
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 2734

Group type: COMPARATOR
Intervention: DURATION-6 (Liraglutide)
Number of subjects: 2734
Study: 26545669

Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum (6 g per day for 6 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ceratonia siliqua (6 g per day for 6 weeks)
Number of subjects: 64
Study: 24233110

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) implemented after training and guideline establishment
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (before implementation of KMC)
Number of subjects: 98
Study: 21525426

Group type: EXPERIMENTAL
Intervention: Group patient visits (4 sessions over 12 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (one‐on‐one)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group patient visits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 19433812

Group type: EXPERIMENTAL
Intervention: Intensive support program (implemented by nutrition and activity specialists)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Inexpensive nurse-led program (involving weigh-ins and encouragement)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-monounsaturated-fat diet
Number of subjects: 200

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 200
Study: 16923561

Group type: EXPERIMENTAL
Intervention: Rituximab-CHOP-ESHAP
Number of subjects: 84

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 84

Group type: COMPARATOR
Intervention: CHOP-ESHAP-HDT
Number of subjects: 84
Study: 15457382

Group type: EXPERIMENTAL
Intervention: HT Immersion Medical Colonoscopy Simulator (no feedback)
Number of subjects: 26
Study: 11769816

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9108861

Group type: EXPERIMENTAL
Intervention: Tricomponent acellular pertussis-diphtheria-tetanus vaccine (fourth dose)
Number of subjects: 5361
Study: 7848225

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of fetal size (including femur length and abdominal circumference)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clinical assessment of fetal size or weight
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fetal femur length
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Abdominal circumference
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ultrasound estimated fetal weight (using 3 different formulas: Shepard, Campbell and CUHK)
Number of subjects: 105
Study: 3076140

Group type: EXPERIMENTAL
Intervention: Pinacidil 12.5 mg bid with Hydrochlorothiazide 12.5 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pinacidil 12.5 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pinacidil 25 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pinacidil 37.5 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinacidil with Hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinacidil (low doses 12.5-25 mg bid)
Number of subjects: 0
Study: 31483187

Group type: EXPERIMENTAL
Intervention: App-connected ovulation test system (n=382)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Control group (n=403)
Number of subjects: 844
Study: 31229307

Group type: EXPERIMENTAL
Intervention: (F-18)Fluorodeoxyglucose positron emission tomography (FDG-PET) studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol (antipsychotic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27997282

Group type: EXPERIMENTAL
Intervention: Community-based physical activity and nutrition program for 6 months
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard diet and physical activity advice on only one occasion (Control)
Number of subjects: 417
Study: 28253848

Group type: EXPERIMENTAL
Intervention: 10-min computer-based Crew Resource Management (CRM) training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control training on ethics
Number of subjects: 57
Study: 23669822

Group type: EXPERIMENTAL
Intervention: Oral treprostinil (3.1 ± 1.9 mg bid)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 21036692

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 26450

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 26450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26450
Study: 19439878

Group type: EXPERIMENTAL
Intervention: IL bleomycin (0.1% solution with concurrent anesthesia)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cryotherapy (double freeze-thaw cycle)
Number of subjects: 73
Study: 18042591

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for induction therapy with corticosteroids for 24 weeks
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for maintenance therapy with corticosteroids
Number of subjects: 358

Group type: COMPARATOR
Intervention: Cyclophosphamide for induction therapy with corticosteroids for 24 weeks
Number of subjects: 358

Group type: COMPARATOR
Intervention: Azathioprine for maintenance therapy with corticosteroids
Number of subjects: 358
Study: 15088305

Group type: EXPERIMENTAL
Intervention: Cetylated fatty acid (CFA) topical cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11318042

Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 204

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 204
Study: 9386902

Group type: EXPERIMENTAL
Intervention: 3-month special diet (17 subjects from the experimental group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Experimental group (hypercholesterolaemia)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (39 healthy normocholesterolaemic subjects; 18 women and 21 men; mean age 43.7 ± 2.18 years)
Number of subjects: 39
Study: 7943076

Group type: EXPERIMENTAL
Intervention: Intravaginal prostaglandin E2 (2.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 (0.5 mg)
Number of subjects: 100
Study: 3293887

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Benzydamine mouthwash
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 25
Study: 29939502

Group type: EXPERIMENTAL
Intervention: History of hypoglycemia
Number of subjects: 2273481

Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin and sulfonylurea
Number of subjects: 2273481

Group type: EXPERIMENTAL
Intervention: Presence of nephropathy
Number of subjects: 2273481
Study: 28277398

Group type: EXPERIMENTAL
Intervention: Therapeutic showering for 30 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual labor care
Number of subjects: 32
Study: 24564262

Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive treatment
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 873

Group type: COMPARATOR
Intervention: Control group (non-ISH patients)
Number of subjects: 873
Study: 22373002

Group type: EXPERIMENTAL
Intervention: Auricular acupressure at five true acupoints (NADA protocol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Auricular acupressure at five sham points
Number of subjects: 60

Group type: COMPARATOR
Intervention: No auricular acupressure at all
Number of subjects: 60
Study: 20684786

Group type: EXPERIMENTAL
Intervention: Structured practice nurse reviews with a specially prepared education booklet and comprehensive baseline assessment, followed by regular 3 monthly reviews over 2 years.
Number of subjects: 558

Group type: COMPARATOR
Intervention: Usual care from general practice (control group).
Number of subjects: 558
Study: 18331207

Group type: EXPERIMENTAL
Intervention: Fetal electrocardiography (FECG) monitoring during labor
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cardiotocography (CTG) monitoring during labor
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Clinical intervention based on significant CTG and ECG changes
Number of subjects: 103
Study: 16884977

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 18
Study: 14979223

Group type: EXPERIMENTAL
Intervention: Triple P-Positive Parenting Program (TP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waitlist control group (WL)
Number of subjects: 91
Study: 10893895

Group type: EXPERIMENTAL
Intervention: Megadose heparin bolus (300 IU/kg body weight)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Streptokinase (1.5 million units over one hour)
Number of subjects: 47
Study: 8671129

Group type: EXPERIMENTAL
Intervention: Eradication therapy for Helicobacter pylori
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (non-dyspeptic attenders)
Number of subjects: 164
Study: 8355105

Group type: EXPERIMENTAL
Intervention: 16 mg methylprednisolone orally the evening before surgery, combined with 20 mg methylprednisolone intravenously immediately preoperatively
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 16 mg methylprednisolone orally and 20 mg intravenously
Number of subjects: 11
Study: 3125098

Group type: EXPERIMENTAL
Intervention: GRF 1-44 at 7.5 micrograms/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GRF 1-44 at 15 micrograms/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (GH therapy)
Number of subjects: 12
Study: 29966108

Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard facemask
Number of subjects: 50
Study: 26195620

Group type: EXPERIMENTAL
Intervention: Advanced reciprocating gait orthosis with dorsiflexion-assist ankle-foot orthoses
Number of subjects: 10
Study: 24096862

Group type: EXPERIMENTAL
Intervention: Simultaneous fitting of bilateral hearing aids
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sequential fitting of bilateral hearing aids
Number of subjects: 36
Study: 23257685

Group type: EXPERIMENTAL
Intervention: mepolizumab (anti-IL-5 monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 20502294

Group type: EXPERIMENTAL
Intervention: Chlorhexidine wipes
Number of subjects: 5008

Group type: COMPARATOR
Intervention: Saline placebo wipes
Number of subjects: 5008
Study: 18561877

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15947613

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 210

Group type: COMPARATOR
Intervention: Phloroglucinol
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 210
Study: 12837122

Group type: EXPERIMENTAL
Intervention: Manipulation of the wrist
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ultrasound, friction massage, and muscle stretching and strengthening exercises
Number of subjects: 28
Study: 11006069

Group type: EXPERIMENTAL
Intervention: Cognitive interventions utilizing interactive telephone counseling
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Behavioral interventions such as patient reminders
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sociologic intervention using video-taped peer discussions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Multiple types of strategies
Number of subjects: 22
Study: 9229322

Group type: EXPERIMENTAL
Intervention: HD-FU/FA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HD-FU/FA/C
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: HD-FU/FA/C/E
Number of subjects: 44
Study: 1334445

Group type: EXPERIMENTAL
Intervention: 2% nedocromil sodium eye drops (twice daily)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eye drops (four times daily)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium eye drops
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate eye drops
Number of subjects: 185
Study: 3881088

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasoconstriction assay
Number of subjects: 0
Study: 30517100

Group type: EXPERIMENTAL
Intervention: Total sport participation at age 12
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Adiposity measures at age 12
Number of subjects: 4033
Study: 25857847

Group type: EXPERIMENTAL
Intervention: i.v. parecoxib sodium 40 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: i.v. placebo (saline) 2 mL
Number of subjects: 64
Study: 24534413

Group type: EXPERIMENTAL
Intervention: PAM with mother's recorded voice
Number of subjects: 94

Group type: COMPARATOR
Intervention: No PAM (control)
Number of subjects: 94
Study: 22398072

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 140
Study: 20592006

Group type: EXPERIMENTAL
Intervention: ATM therapy (N=47)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition (financial workbook review, N=43)
Number of subjects: 90
Study: 18534139

Group type: EXPERIMENTAL
Intervention: LTRA(+) (pranlukast, treated for 3 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LTRA(-) (no pranlukast)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LTRA(+) (pranlukast)
Number of subjects: 29
Study: 16001906

Group type: EXPERIMENTAL
Intervention: Traditional training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional training with biofeedback
Number of subjects: 30
Study: 12461494

Group type: EXPERIMENTAL
Intervention: 37.5 microg/day (group 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 62.5 microg/day for 3 days, then 37.5 microg/day (group 2)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 50 microg/day (group 3)
Number of subjects: 47
Study: 10367992

Group type: EXPERIMENTAL
Intervention: PTSD patients listening to combat sounds
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PTSD patients listening to white noise
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control groups (combat-exposed subjects without PTSD and healthy control subjects) listening to combat sounds
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control groups (combat-exposed subjects without PTSD and healthy control subjects) listening to white noise
Number of subjects: 35
Study: 7562765

Group type: EXPERIMENTAL
Intervention: Spa therapy + routine drug therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Routine drug therapy
Number of subjects: 121
Study: 1696795

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) as volume replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP) and human albumin (HA)
Number of subjects: 0
Study: 7438972

Group type: EXPERIMENTAL
Intervention: Oral fenoterol 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral fenoterol 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral fenoterol 7.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31772506

Group type: EXPERIMENTAL
Intervention: High day 1 dsDNA levels (>median; 366 ng/ml)
Number of subjects: 259
Study: 27852999

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tuberculin purified protein derivative
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 26087078

Group type: EXPERIMENTAL
Intervention: Disease agency language assigned to humans (e.g., 'I developed cancer')
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Death-approach language (e.g., 'as death closes in on patients')
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Human-approach language (e.g., 'as patients close in on death')
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Transportation and identification
Number of subjects: 499
Study: 23327232

Group type: COMPARATOR
Intervention: Saliva contamination after primer application (group 2)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Saliva contamination after primer and before bonding (group 3)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Saliva contamination after bonding (group 4)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Saliva contamination after light polymerization of the bonding agent (group 5)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Saliva contamination after light polymerization with removal of contaminated layer (group 6)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 180
Study: 21358561

Group type: EXPERIMENTAL
Intervention: Combination of clonazepam (1 mg once daily) and Deanxit for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonazepam (1 mg once daily) and placebo for 3 weeks
Number of subjects: 0
Study: 19952790

Group type: EXPERIMENTAL
Intervention: Job-specific occupational health education program
Number of subjects: 205

Group type: COMPARATOR
Intervention: Conventional program
Number of subjects: 205
Study: 17971582

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two-Dimensional Radiation Therapy (2DRT)
Number of subjects: 60
Study: 15115903

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 0.5 mg after oral placebo (OP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 0.5 mg after 80 mg isosorbide dinitrate (ISDN)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) 0.5 mg after 120 mg isosorbide dinitrate (ISDN)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) after long-term OP therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) after long-term 80 mg ISDN therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG) after long-term 120 mg ISDN therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg once-daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg once-daily
Number of subjects: 38
Study: 11763107

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg t.i.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9893926

Group type: EXPERIMENTAL
Intervention: Timonil retard (test formulation)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 21
Study: 8061389

Group type: EXPERIMENTAL
Intervention: Chemotherapy (5-fluorouracil, its analogues, and mitomycin C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 0
Study: 2657837

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gepirone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 947849

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (700 IU)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Whole virus vaccine (2100 IU)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Subunit vaccine (2100 IU)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Split vaccine (800 IU)
Number of subjects: 399
Study: 31415827

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 170
Study: 29064884

Group type: EXPERIMENTAL
Intervention: Preoperative oral antibiotics and intravenous antimicrobial prophylaxis
Number of subjects: 335

Group type: COMPARATOR
Intervention: Intravenous antimicrobial prophylaxis alone
Number of subjects: 335
Study: 29546345

Group type: EXPERIMENTAL
Intervention: Multivitamin use before diagnosis
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Multivitamin use during treatment
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Other supplement use (before diagnosis or during treatment)
Number of subjects: 1225
Study: 25023433

Group type: EXPERIMENTAL
Intervention: 20 mg intravenous hyoscine-N-butyl bromide (HBB)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (1 mL saline)
Number of subjects: 2
Study: 24175604

Group type: EXPERIMENTAL
Intervention: 20% burst duty cycle of medium-frequency alternating current
Number of subjects: 0

Group type: COMPARATOR
Intervention: 35% burst duty cycle of medium-frequency alternating current
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50% burst duty cycle of medium-frequency alternating current
Number of subjects: 0

Group type: COMPARATOR
Intervention: All burst duty cycles (20%, 35%, 50%)
Number of subjects: 0